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Intranuclear inclusion bodies (IBs) are the histopathologic markers of multiple protein folding diseases. IB formation has been
extensively studied using fluorescent fusion products of pathogenic polyglutamine (polyQ) expressing proteins. These studies
have been informative in determining the cellular targets of expanded polyQ protein as well as the methods by which cells rid
themselves of IBs. The experimental thrust has been to intervene in the process of polyQ aggregation in an attempt to alleviate
cytotoxicity. However new data argues against the notion that polyQ aggregation and cytotoxicity are inextricably linked
processes. We reasoned that changing the protein context of a disease causing polyQ protein could accelerate its precipitation
as an IB, potentially reducing its cytotoxicity. Our experimental strategy simply exploited the fact that conjoined proteins
influence each others folding and aggregation properties. We fused a full-length pathogenic ataxin-1 construct to fluorescent
tags (GFP and DsRed1-E5) that exist at different oligomeric states. The spectral properties of the DsRed1-E5-ataxin-1
transfectants had the additional advantage of allowing us to correlate fluorochrome maturation with cytotoxicity. Each fusion
protein expressed a distinct cytotoxicity and IB morphology. Flow cytometric analyses of transfectants expressing the greatest
fluorescent signals revealed that the DsRed1-E5-ataxin-1 fusion was more toxic than GFP fused ataxin-1 (31.864.5% cell death
versus 12.8563%), although co-transfection with the GFP fusion inhibited maturation of the DsRed1-E5 fluorochrome and
diminished the toxicity of the DsRed1-E5-ataxin-1 fusion. These data show that polyQ driven aggregation can be influenced by
fusion partners to generate species with different toxic properties and provide new opportunities to study IB aggregation,
maturation and lethality.
Citation: Rich T, Varadaraj A (2007) Ataxin-1 Fusion Partners Alter PolyQ Lethality and Aggregation. PLoS ONE 2(10): e1014. doi:10.1371/
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INTRODUCTION
Aberrant protein folds, expressed in post mitotic cells such as
neurons, are the precursors of multiple neurodegenerative diseases
[1]. A characteristic of the proteins that express these pathogenic
folds, for example polyglutamine (polyQ) containing proteins, is
their aggregation into intra-nuclear inclusion bodies (IBs).
However the role played by IBs in the disease process remains
controversial [2] and IBs may be preceded by toxic oligomers
[3,4]. The expression of pathogenic ataxin-1 protein carrying
expanded tracts of polyQ results in Spinocerebellar Ataxia type 1,
a disease that decimates cerebellar Purkinje cells and brain stem
neurons [5]. The existence of heterogeneous IBs nucleated by
expanded ataxin-1 suggests multiple aggregation pathways or
oligomeric precursors and the possibility to influence ataxin-1
folding. We now investigate this possibility using fusion proteins of
ataxin-1.
We chose to study the toxic species of ataxin-1 that expresses an
expanded polyQ repeat as our aim was to modulate the toxicity of
this species using protein domains distal to the repeat. Our aim
was not to compare the toxicity of ataxin-1 proteins that express
different polyQ repeat lengths as these studies have been
completed by numerous groups and would not be informative
for this study of pathogenic ataxin-1 fusions. Instead we chose to
exploit the finding that linked proteins alter each others folding
pathways [6–8]. A protein that aggregates will retard the folding of
Green Fluorescent Protein (GFP) [9]. Likewise the substitution of
GFP with another tag that exists as a higher order oligomer could
alter the folding of a pathogenic protein to which it is fused, and
potentially its lethality. Thus far the research impetus has been to
increase the solubility of polyQ proteins in an effort to decrease
toxicity, as IB formation is regarded by many to be a cytotoxic
event. However, oligomeric species of polyQ may be the bona-fida
toxic species and much recent data would support this notion
[3,6,8]. If this is the case, accelerated aggregation, depleting
oligomeric ataxin-1 species, may be cytoprotective. We explored
this possibility by expressing cDNAs of A. victoria EGFP and
Discosoma DsRed1-E5 fused upstream of an ataxin-1 construct that
encodes eighty-two contiguous polyglutamines. GFP naturally
exists as a monomer/dimer whilst DsRed1-E5 is an obligate
tetramer/octamer [10,11]. Having engineered and expressed
fusion proteins of both GFP and DsRed1-E5 fused at their
carboxyl termini to ataxin-1 expressing an expanded polyQ repeat
we found that transfectants of either species expressed conspicuous
intra-nuclear IBs, though the fluorescent nucleoplasmic fraction
typically seen in GFP-ataxin-1 transfectants was absent in
DsRed1-E5-ataxin-1 transfectants. The kinetics of IB deposition
was modified by the different fusion species, though both species of
IB could sequester PML-NDs, a finding which suggests a common
pathogenic property of these and perhaps many other pro-
teinaceous aggregates. Transfectants expressing DsRed1-E5-
ataxin-1 suffer reduced viability compared to those expressing
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GFP-ataxin-1 or expression of a shortened glutamine repeat.
Collectively, these data show that the biologic properties of IBs
seeded by the same pathogenic ataxin-1 protein can be markedly
altered by its fusion to different protein tags and that accelerated
IB formation was not cyto-protective in this experimental system.
RESULTS
Altered expression pattern and IB morphology of
ataxin-1 fusion proteins
Untagged, GFP and DsRed1-E5 fusions of a pathogenic ataxin-1
construct were transiently transfected into HeLa cells. DsRed1-E5
is a mutant of the DsRed1 protein and fluoresces green when first
synthesised, then after a few hours, red [11]. This colour change is
contingent on DsRed1-E5 folding into its tetramer/octameric state
[12]. Fluorescence microscopy of ataxin-1 transfectants, with
immunostains for untagged ataxin, revealed striking variations in
expression pattern for the fusion proteins. Unless otherwise stated,
ataxin-1 refers to ataxin-1 expressing an expanded glutamine
repeat with 82 glutamines.
Untagged ataxin-1 (immuno-stained with an anti polyQ mono-
clonal antibody 1C2) and GFP fused ataxin-1 were found to be
expressed as both nuclear IBs and dispersed throughout the
nucleoplasmic fraction as granular material that excluded the
nucleoli (Figure 1A). Nucleoplasmic ataxin-1 is thought to
comprise oligomeric species that precede IB formation; a notion
supported by the expression of nucleoplasmic GFP-ataxin-1 in
nuclei entirely devoid of IBs and its diminution as IBs nucleate
[10]. In GFP-ataxin-1 transfectants, the majority of cells (82%63
(n=100)) expressed both nucleoplasmic and IB nucleated ataxin-1
with the remaining cells expressing a nucleoplasmic fraction only.
7568% (n=100) of GFP-ataxin-1 containing IBs were dense with
no obvious substructure. The remainder were reticular as we have
previously shown [13]. Interestingly, IB morphology was nucleus
specific, suggesting a shared driver such as local protein
concentration. Note that for ataxin-1, expression of an expanded
glutamine repeat in cell culture increases the frequency of nuclei
that express large IBs ($ 1 micron in diameter). The majority of
transfectants express IBs whether transfected with normal or
expanded ataxin-1 [14], with the frequency of large IBs
diminished in transfectants expressing ataxin-1[Q30].
In contrast to the GFP fusion, DsRed1-E5-ataxin-1 was
expressed as reticular intranuclear and cytoplasmic IBs similar to
those reported for nuclear aggresomes [15], aggregates of RED
protein [13] and certain cytoplasmic puncta (Figure 1B) [16]. High
magnification imaging at low voltage revealed the reticular IB
structure which can be obscured by pixel saturation at higher
voltages (Figure 1B, lower right). The lack of a diffuse or
oligomeric nucleoplasmic fraction, as suggested by the loss of
fluorescence in this compartment, was confirmed by immunostains
with the 1C2 antibody (data not shown). As for the GFP fusion,
transfectants expressing DsRed1-E5 fused to ataxin-1 expressing
a normal polyQ repeat length [Q30] expressed smaller IBs, still
with no evident nucleoplasmic fraction (data not shown). Both
green and red fluorescence, attributable to immature and mature
DsRed1-E5, was evident in each IB, regardless of size. Large intact
cytoplasmic IBs of DsRed1-E5-ataxin-1 frequently deformed the
nuclear envelope (Figure 1B, inset), in common with nuclear pore
complexes seen in Alzheimers disease [17]. The perinuclear
location of these proteins prompted us to address whether they
reorganised vimentin–a characteristic of the aggresome. However,
immunostains for vimentin failed to indicate its disruption by
cytoplasmic IBs of DsRed1-E5-ataxin-1 (data not shown).
DsRed1-E5-ataxin-1 IBs nucleate synchronously
The existence of heterogeneous IBs pointed to a role for kinetics in
shaping inclusion body morphology and ataxin-1 distribution. To
address this we took advantage of the spectral properties of
DsRed1-E5 to investigate the seeding process itself. DsRed1-E59s
colour transition is independent of protein concentration, allowing
us to discriminate between newly synthesized versus mature
protein. This property would also allow us to study the mode of
aggregation, for example by identifying a core of older protein.
Confocal microscopy was used to measure the fluorescence
intensity across equatorial sections (at .05/.06 micron intervals)
of individual IBs in DsRed1-E5-ataxin-1 transfectants (Figure 1C).
Ratios of green and red fluorescence were found to be highly
conserved across individual inclusions (Figure 1C, Table 1) with
synchronous spikes and troughs detected at both wavelengths. A
striking intranuclear but not internuclear conservation of g/r ratio
was also apparent (Figures 1C and 1D, Table 1). However there
was no clear relationship between IB diameter and g/r ratio
(Table 2). These data suggested the synchronous deposition of IB
populations in each nucleus. To test the influence of the DsRed1-
E5 moiety as a driver for synchronous IB seeding we expressed
a second DsRed1-E5 fusion, this time to the promyelocytic
leukaemia protein (PML) [18]. PML is the principle structural
constituent of PML nuclear domains, stress responsive polymeric
structures that are disrupted by protein aggregates [19,20]. In
contrast to DsRed1-E5-ataxin-1, fluorescence microscopy of
nuclear puncta seeded by DsRed1-E5 fused to PML revealed
bodies of quite different maturity and fluorescence (Figure 2A).
Clearly then, fusion to DsRed1-E5 alone is not sufficient to result
in simultaneously seeded structures.
Maturation of the DsRed1-E5 fluorochrome is
inhibited by co-expression with GFP-ataxin-1
Expression of ataxin-1 was also examined in co-transfected Hela
nuclei to assess the dominance of either fusion in altering viability.
Twenty-four hours after co-transfection into HeLa cells the
predominant expression pattern (in 7864%) were cells expressing
intense diffuse green nucleoplasmic fluorescence and intranuclear
IB’s with emission maxima characteristic of GFP-ataxin-1.
Occasional red fluorescence was as cytoplasmic IBs or small
punctate intranuclear aggregates (Figure 2A). Cytoplasmic IBs of
mature DsRed1-E5-ataxin-1 are found in single transfectants
(Figure 1A) and arise as protein formed during the first interphase
after transfection becomes trapped in the cytoplasm after mitosis
(confirmed by cell cycle synchronisation experiments-data not
shown). However, the striking and reproducible difference
between single and double transfectants expressing DsRed1-E5
fused ataxin-1 was the reduction of intranuclear red fluorescence.
These data suggested a model in which maturation of DsRed1-E5-
ataxin-1 was inhibited in the nuclear compartment, when co-
expressed with the GFP fused ataxin-1. To quantitatively test this
we exploited the difference in emission spectra between GFP and
DsRed1-E5 to identify the dominant fluorescent signature in
double transfectants. Flow cytometric density plots of GFP-ataxin-
1 transfectants (Figure 2B) revealed green fluorescent cells of low
to high fluorescence intensity (denoted by boxed regions 1–5). The
red fluorescence in transfectants with the highest green fluorescent
intensity is due to the compensation level, which could not be
increased if the less fluorescent cells were not to dip beneath the
detection threshold. The degree of compensation used was
sufficient to allow all fluorescent events to be visualised. The
clustering of fluorescent events in boxes 4 and 5 (a consistent event)
may indicate the fluorescence due to folding intermediates.
IB Modified by Fusion Protein
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a diagonal (Figure 2A, middle panel), with immature green
fluorescent DsRed1-E5-ataxin-1 becoming redder (and greener)
with increasing time after transfection. Again these cells could be
grouped according to increasing fluorescence intensity and each
group could be analysed individually for viability. In double
transfectants (Figure 2B, RH Panel) the fluorescence signature
attributable to DsRed1-E5-ataxin-1 is ablated, and a dominant
green fluorescent signature, characteristic of GFP-ataxin-1 evident
(Figure 2B, right hand panel). Only a small increase in cell
number is seen in the region indicated in the two density plots
(Figure 2C).
GFP-ataxin-1 expression is cytoprotective for
DsRed1-E5-ataxin-1 transfectants
Recent data suggests that oligomeric forms of polyQ protein are
cytotoxic [3,6,21]. The preference for IB formation by the
DsRed1-E5 versus GFP fused ataxin-1 protein suggested to us
that the DsRed1-E5 fusion aggregated differently. To assess
whether enhanced IB formation also impacted cytotoxicity we
tested cell viability using two assays. The first is an MTT based
assay that measures cellular reducing power as a correlate of viable
cell number. The second assay measures dye uptake, with reduced
viability leading to increased membrane permeability and
Figure 1. Expression patterns of ataxin-1 fusion proteins. Figure 1A. Distribution of ataxin-1 and ataxin-1-GFP. Upper panel; untagged ataxin-1
stained with 1C2 with a DAPI merge; lower panel, GFP-ataxin-1 with DAPI merge. Figure 1B. DsRed1-E5-ataxin-1 emits both red (r) and green (g)
fluorescence. The merged red green and red/DAPI fluorescence micrographs are also shown. An orthogonal slice through a reticular IB seeded by
DsRed1-E5-ataxin is shown lower right. Scale bars: 8 microns. Figure 1C. IBs of DsRed1-E5-ataxin express protein of comparable age. Synchronous
peaks and troughs of red/green fluorescence emitted by IBs of DsRed1-E5-ataxin in shared nuclei. IBs are ranked according to maturity; with high g/r
ratios indicating immature protein. Figure 1D. Synchronous seeding of DsRed1-E5-ataxin IBs. HeLa nuclei were ranked according to mean g/r ratio of
their IB populations (24hr after transfection). 169 IBs in 16 nuclei were included in this data set.
doi:10.1371/journal.pone.0001014.g001
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they do not bias towards any particular form of cell death; being
inclusive of both secondary apoptotic and necrotic events.
Viability was also correlated with the ablation of fluorochrome
maturation in double transfectants. Cells with high versus low
fluorescence intensity for either fusion protein were selected (boxed
regions in Figure 2B) and their DAPI uptake assessed to determine
membrane integrity. Cells expressing the highest fluorescent signal
attributable to GFP-ataxin-1 (box 5) were found to have a dye
permeable fraction of 12.8563% (Figure 2D). Similar measure-
ments with DsRed1-E5-ataxin-1 transfectants showed an in-
creased dye uptake of 31.864.5% of cells (Figure 2D). In double
transfectants viability was comparable to the GFP-ataxin-1
expressing cells (dye permeable cells; 14.462.3%). These trends
were comparable with a second viability assay that measures the
reducing power of identical numbers of each transfectant pool
(Figure 2E). However, equivalent viability assays for GFP and
DsRed1-E5 fused ataxin-1[Q30] revealed low levels of toxicity for
either fusion species. In the case of normal polyQ repeat lengths,
the DsRed1-E5 moiety had no significant effect on toxicity.
PML-NDs are sequestered by both species of ataxin-
1 fusion proteins
One property of pathogenic ataxin-1 protein is to sequester and
disrupt specific nucleoproteins such as promyelocytic leukaemia
nuclear domains (PML-NDs) [18,20,22]. We tested whether
sequestration of PML-NDs was demonstrable for IBs seeded by
DsRed1-E5-ataxin-1, as previously shown for GFP-ataxin-1.
Using DsRed1-E5-ataxin-19s property of emitting dual red and
green fluorescence combined with immunostains with a pan PML
antibody we identified sequestered PML-NDs (Figures 2F/G).
Sequestered PML is evident in the fluorescent micrograph in
Figure 2F. 9265% of IBs over 1 micron in size sequestered PML-
NDs. Previously we showed irreversible PML-ND sequestration by
protein inclusions in stressed cells [20]. Similar assays for the
irreversibility of PML-ND sequestration following heat shock
revealed sequestered PML-NDs on 9066% of DsRed1-E5-ataxin-
1 IBs and 9364% of GFP-ataxin-1 IBs of over 1 mm in diameter.
DISCUSSION
IBs are the terminal stage of a series of aggregation steps, leading
us to predict that IB morphology, lethality, and formation kinetics
may reflect the preceding aggregation processes. We now
demonstrate this biologic heterogeneity using IBs seeded by an
identical polyQ repeat expressed in the context of different
fluorescent protein tags.
It is widely thought that the toxicity of polyQ proteins is, in part,
due to their sequestration of nucleoproteins such as PML-NDs and
typical PML-NDs are found in several neuronal species [23,24].
Irreversible sequestration of nucleoprotein effectors increases
cellular sensitivity to injury [25]. For both ataxin-1 fusions we
identified irreversibly bound PML-NDs following heat shock,
a stress that ordinarily fragments PML-NDs [20]. PolyQ diseases
are thought to be a disease of transcription. Crucially, PML-NDs
contain cargo proteins, amongst them chromatin modifiers, that
are released into the nucleoplasm following PML-ND fragmenta-
tion [19]. Disruption of these processes may be cytotoxic to the cell
and, in the context of our experiments, may be provoked by either
ataxin-1 fusion expressing an expanded repeat. The question arises
as to why PML-NDs are so susceptible to disruption by protein
aggregates. One possibility is that PML-NDs are part of the
intranuclear apparatus to monitor abnormal accumulations of
proteins [26] and nucleic acid, in a similar fashion to cytoplasmic
Trim5 [27]. As such, PML-NDs may be recruited to sites of
protein deposition, which results in their sequestration. The
recruitment of PML-NDs to sites of ionising radiation induced foci
(IRIF) may be another example of PML-NDs detecting high
concentrations of protein and disturbed chromatin [28]. Recent
data has shown the translocation of PML towards sites of viral
intrusion [29]. The inset micrograph in Figure 2G may indicate
a similar translocation of PML protein, though this would have to
be confirmed by live cell imaging which is currently unreliable
given the artefactual activity recorded for ectopic PML transfec-
tants [28].
Co-expression of both ataxin-1 fusions resulted in a dramatic
loss of red fluorescence, probably through sequestration of
immature DsRed1-E5-ataxin-1 by GFP-ataxin-1, which may then
be locked into an unfavourable fold for maturation. This may
explain the small diameter of red puncta in double transfectants;
Table 1. Green/Red Fluorescence ratios in IBs of DsRed1-E5-
ataxin-1 IBs.
......................................................................
IB Diameter (mm) g/r Fluorescent Ratio (mean6SD)
Nucleus 1 1.98 1.5660.29
2.32 1.5460.24
Nucleus 2 2.09 0.5660.08
2.38 0.6360.11
Nucleus 3 4.33 0.8760.10
3.20 0.9460.13
Equatorial line scans through IBs were used to generate g/r ratios. Mean g/r
fluorescence ratios are shown for three pairs of IBs (in separate nuclei).























































Table 2. Non-linear relationship between g/r ratio and IB
diameter.
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Mean fluorescence ratios calculated for the IBs populations shown in Figure 1C.
For each nucleus the mean g/r ratio is shown, with the diameter of the largest
and smallest IB in that nucleus. These data reveal the lack of any linear
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1014Figure 2. IB properties and lethality of ataxin-1 fusion proteins. Figure 2A. Distribution of DsRed1-E5-PML and dual transfected ataxin-1 fusions. LH
panel; puncta of DsRed1-E5-PML reveal heterogeneous red/green fluorescence (arrowed) in a HeLa transfectant. Ne denotes nuclear envelope. Scale
bar: 8 microns. RH panel; cytoplasmic enrichment of aged DsRed1-E5-ataxin in dual transfectants. Green and red indicates the wavelengths scanned
in each micrograph, with DAPI co-stain. Scale bar: 15 microns. Figure 2B. Red/green fluorescence in single and co-transfectants of ataxin-1 fusion
proteins. LH panel; GFP-ataxin-1; Middle panel; DsRed1-E5-ataxin-1; RH panel; dual transfectants. Figure 2C. Enriched red fluorescence in co-
transfectants occurs in the region indicated. Figure 2D. Dye uptake shows increased lethality of DsRed1-E5-ataxin-1. Increased DAPI uptake is seen in
DsRed1-E5-ataxin-1 versus GFP-ataxin-1 and Dual transfectants. Figure 2E. Cell proliferation assay shows reduced viability in DsRed1-E5-ataxin-1
transfectants. MTT based assay of DsRed1-E5 (Ds), GFP (G) and dual (x2) transfectants, comparing ataxin-1 expressing both normal [Q30] and
expanded polyQ repeats [Q82]. Figure 2F. PML-NDs are sequestered by IBs of DsRed1-E5-ataxin-1. Histogram of red/green fluorescence across
a DsRed1-E5-ataxin-1 transfectant, stained with N19. Spikes of red fluorescence (darker line) denote PML-NDs tethered to IBs in a single nucleus.
Figure 2G. PML/DsRed1-E5-ataxin-1 sequestration. Scale bar: 8 microns. Inset; ataxin-1/PML sequestration captured by immunofluorescent staining of
endogenous PML (red) with GFP-ataxin-1. Scale bar: 15 microns. Figure 2H. Mobility of DsRed1-E5-ataxin-1 IBs revealed by time-lapsed confocal
microscopy. 9-section Z series were collected every 5 minutes for an hour. The four frames shown indicate fusion events over twenty minutes in
a single optical section. Multiple fusion events occur within the boxed region. The arrowed IB also tracks towards this region. The disordered
fluorescence at the extremities of the nucleus corresponds to cytoplasmic material.
doi:10.1371/journal.pone.0001014.g002
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The loss of red fluorescence does not imply that the DsRed1-E5-
ataxin-1 protein has not aggregated. Rather it shows that the
folding pathway followed by this fusion form of ataxin-1 is such
that the DsRed1-E5 moiety has failed to form a tetramer, which is
necessary for it to fluoresce. Critically, it is this failure to express
red fluorescence which correlates most strongly with lethality. The
co-aggregation of DsRed1-E5-ataxin-1 with GFP-ataxin-1 protein
probably prevents DsRed1-E5 tetramer formation. One caveat to
these data is that the detection of small fluorescent puncta by flow
cytometry is less efficient than that of larger aggregates or diffusely
expressed material; which could lead to the under-estimation of
DsRed1-E5-ataxin-1 puncta. None-the-less, the loss of the
DsRed1-E5 fluorescence signature in double transfectants is
a potent illustration of how different species of fusion protein
can influence each-others folding characteristics.
Our experimental strategy also allowed us to investigate IB
seeding as we could retrospectively gauge the maturity of protein
within individual IBs. The fluorescence profiles of DsRed1-E5-
ataxin-1 IBs suggested that they synchronously nucleate from
material of similar maturity. Mobility and fusion of large
intranuclear IBs [16,30] also supports the notion that IB resident
proteins are not wholly insoluble and that IB interaction continues
after initial seeding events, so preserving the green/red fluores-
cence ratios. The mobility of DsRed1-E5-ataxin-1 IBs would
support this notion (Figure 2H).
The lethality of the DsRed1-E5-ataxin-1 fusion was evident by
dye uptake and metabolic assays, even at low levels of
fluorescence, and was attenuated in double transfectants. These
data are consistent with the generation of a toxic DsRed1-E5-
ataxin-1 species whose toxicity is diminished by co-expression with
GFP-ataxin-1. The reduction of toxicity in double transfectants
and the minimal maturation of the DsRed1-E5 fluorochrome
suggests that the two events are linked. Folding of the DsRed1-E5
fluorochrome and a mature red fluorescent signal was associated
with toxicity. At this stage we do not know if the intermediate
folding species are the same for either aggregate; future work will
address these issues. MTT based assays showed similar toxicities
for DsRed1-E5 and GFP fused ataxin-1[Q30]. Recent work [6]
has suggested that fusion tags can act as templates for the
aggregation of polyQ repeats, with expanded repeats acting to
accelerate aggregation. Our data would agree with this hypothesis.
Additionally the DsRed1-E5 template only serves as a primer for
a toxic folding pathway when expressed with an expanded polyQ
repeat. Future work will allow us to generate a bank of primers
that are both cytoprotective and deleterious to the health of the
cell, in order to delineate the aggregation pathways that can be
accessed to diminish toxicity.
The toxicity of the DsRed1-E5 fusion of ataxin-1 is consistent
with recent reports of other highly toxic reticulated species of
inclusion[31]. Whether or not these species arise in polyQ
pathologies will need to be addressed. Further experiments will
be required to assess the toxicity of DsRed1-E5 in other cell types.
The data that we report here for HeLa transfectants was found to
be reproducible in neuroepithelial HEK293 cells, though we have
not extended these experiments to untransformed neuronal cells.
The possibility of altered forms of cell death active in neuronal
lineages versus other cell types is another important consideration
[32]. Further, the potent inhibition of DsRed1-E5 maturation and
toxicity by the GFP fusion form of ataxin-1 may indicate the
success with which polyQ species can influence and ultimately
disrupt multiple sub-nuclear targets. These in-vitro cell systems are
powerful tools with which to test protein aggregation but we must
take into consideration the kinetics of protein accumulation in
these models. The possibility remains that rapid IB formation in
cell culture is an overtly cytotoxic event that masks more subtle
underlying pathologies that arise from the sequestration of
bystander proteins by polyQ species. Additionally, PolyQ inclu-
sions grow rapidly once seeded, but the initial seeding event is
preceded by a lengthy lag phase during which pre-IB polyQ protein
is expressed[33]. During this lag phase, the cell may employ injury
pathways to adapt to the presence of polyQ protein. These adaptive
injury responses may not be expressed in cell culture models because
of the rapidity of IB formation. We are currently testing these
hypotheses by using PML-NDs as stress markers in cells expressing
low amounts of oligomeric polyQ protein.
MATERIALS AND METHODS
Plasmid constructs
GFP-ataxin-1 encoding 82 and 30 contiguous glutamines were
gifts from Professor H. Zoghbi (Baylor, USA) and Professor H.
Okazawa (Tokyo Medical and Dental University, Japan). DsRed1-
E5-ataxin-1and DsRed1-E5/PML (PML-VI) cDNAs were assem-
bled in pTimer (Invitrogen, Paisley, UK) and expressed in
pcDNA3.1 (Invitrogen).
Transient Transfection, Immuno-cytochemistry and
Heat Shock
Transient transfection was with Fugene 6 (Roche Applied Science,
Basel, Switzerland) and immuno-staining and heat shock was as
described previously [20]. 1 mg of each construct was used for
transfections, with co-transfections carried out with 2 mg total
DNA. To compare dual and single transfectants, an additional
1 mg control–non-fluorescent empty vector was included in each
single transfection reaction. Anti-PML (clone N19, Santa Cruz,
CA, USA) was used at a dilution of 1/250 and anti-polyQ (clone
IC2, Chemicon Europe, Hampshire, UK) at 1/10,000. IB
quantitation was by ocular counts of multiple fields using a Zeiss
Axiophot fluorescence microscope. At least 100 nuclei were
counted for each data set.
Flow Cytometry and Viability
Cells were scraped from dishes and washed in calcium/
magnesium free PBS to avoid clumping. Analysis was either
directly or following the inclusion of DAPI for cell viability assays.
Acquisition was with a 3 laser MoFlo cytomation cell sorter and
analysis was with CELLQuest (Becton Dickinson) and Summit
offline v3.1 software. Live/dead discrimination was by the
inclusion of 100 ng/ml DAPI reagent. FL5 (DAPI) versus FSC
was used to collate live/dead ratios from a gated set that excludes
doublets. At least thirty thousand events were collected for each
experiment. To ‘back-of’ the fluorescence of high GFP-ataxin-1
expressers (to facilitate compensation), a neutral density condenser
was used. The CellTiter 96H AQueous one Solution Cell Pro-
liferation Assay (Promega) is a colorimetric method for de-
termining viable cell number (based on the MTT assay). This
assay was performed according to manufacturer’s instructions
using identical cell numbers (10,000) seeded into 96 well plates.
24 hours after transfection, % loss of viability was calculated by
measurements of soluble formazan. Fluorescence microscopy was
used to confirm equivalence of transfection efficiency.
Confocal microscopy
Confocal microscopy was with the DM IRBE Leica Confocal
microscope. Z series stacks were assembled as maximum pro-
jection images using the Leica Confocal Software version 2.5. A
IB Modified by Fusion Protein
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image acquisition. For calculations of the ratios of red/green
fluorescence we first ensured that fluorescence intensities were not
distorted by differential rates of bleaching. Fluorescence ratios
were calculated from the mean relative fluorescence intensities
over a section delineated through each IB. ‘Glow Over Under’
mode was used to minimise pixel saturation. Time lapse
microscopy was with cells seeded on a cover-slip and inserted
into a heated chamber. Fields of newly transfected cells were
identified by epifluorescence then imaged as Z stack series every
5 minutes by confocal microscopy. HEPES buffered media and
phenol-red free media were used. Serial Z series were collected for
9 optical sections, averaged 3 times over three channels, red
(568 nm) green (468 nm) and phase contrast, at a resolution of
5126512 and zoom set at 2.4. An HCX PL APO 63.061.20
corrected for UV objective was used.
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